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Abstract
Background: CD20 is a cell surface protein exclusively expressed on B cells. It is a clinically validated target for Non-
Hodgkin’s lymphomas (NHL) and autoimmune diseases. The B cell receptor (BCR) plays an important role for development
and proliferation of pre-B and B cells. Physical interaction of CD20 with BCR and components of the BCR signaling cascade
has been reported but the consequences are not fully understood.
Methodology: In this study we employed antibodies against CD20 and against the BCR to trigger the respective signaling.
These antibodies induced very similar expression patterns of up- and down-regulated genes in NHL cell lines indicating that
CD20 may play a role in BCR signaling and vice versa. Two of the genes that were rapidly and transiently induced by both
stimuli are CCL3 and CCL4. 4 hours after stimulation the concentration of these chemokines in culture medium reaches a
maximum. Spleen tyrosine kinase Syk is a cytoplasmic tyrosine kinase and a key component of BCR signaling. Both siRNA
mediated silencing of Syk and inhibition by selective small molecule inhibitors impaired CCL3/CCL4 protein induction after
treatment with either anti-CD20 or anti-BCR antibodies.
Conclusion: Our results suggest that treatment with anti-CD20 antibodies triggers at least partially a BCR activation-like
response in NHL cell lines.
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Introduction
Activation of B cells is a tightly controlled process. One major
component of these complex control mechanisms is the B cell
antigen receptor (BCR) [1], a multimeric complex of membrane
proteins with at least two immunoglobulin molecules together
with CD79a/b in the core-unit and many accessory proteins [2].
The complexity of the downstream signaling events can lead to
distinct outcomes (development, differentiation, apoptosis or
activation of B lymphocytes), depending on the maturation state
of the cell, magnitude and duration of activation, and modulating
signals from other pathways (eg. CD40, CD19, CD45, CD22,
PIR-B, CD32/FccIIB) [3]. B cells that escape from this control
can give rise to leukemia or lymphoma [4]. In recent years the
anti-CD20 antibody rituximab has led to major improvements in
the treatment of NHL and rheumatoid arthritis [5]. Besides
riuximab which is a so called type I anti-CD20 antibody, type II
antibodies are scrutinized at the moment. In addition to ADCC
and CDC, mediated via the Fc-part of an anti-CD20 antibody,
mostly the so called type II anti-CD20 antibodies also cause
direct cell death by binding CD20 [6] - but the exact contribution
of these different molecular mechanisms to efficacy is not yet fully
understood [7,8].
CD20 (official gene symbol is MS4A1) is a B cell specific,
tetraspanning membrane protein of unknown function without a
known ligand. Several observations point to an interrelation with
the BCR: In the absence of rescuing/anti-apoptotic signals B cells
in culture undergo apoptosis/cell death after crosslinking BCR as
well as after crosslinking CD20 [9–14]. Immunofluorescence
experiments showed that BCR and CD20 co-localize in lipid rafts
upon treatment with type I CD20 antibodies [15]. There also
seems to be a common connection with calcium flux [16,17].
Similar phospho-protein patterns have been described, which led
to the speculation that CD20 may ‘‘hijack’’ BCR signaling
components [16]. Moreover, direct physical coupling of CD20 and
BCR has been reported [18].
Although there are a few other examples of agonistic antibodies
triggering signal cascades is not a common feature of antibodies.
Therefore it is noteworthy that anti-CD20 and anti-BCR
antibodies may activate interfering signal transduction [19,20]. A
signaling cascade at least in part common to BCR and CD20 has
also strongly been implicated by the facts that a survival factor for
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16596B cells called BAFF (TNFSF13B) is able to block apoptosis
mediated by both [21] and that expression of six genes changed
similarily after treatment with anti-CD20 and BCR antibodies
[22].
The goal of this study was to test on the whole transcriptome
level whether concordant gene expression changes occur after
BCR activation and anti-CD20 antibody treatment of human
lymphoma cells.
Results
Effect of anti-BCR treatment on the level of transcription
Because expression of IgM (immunoglobulin M) is a hallmark of
B cells and most lymphoma cell lines contain IgM as immuno-
globulin part of the BCR [21,23] anti-IgM antibodies are
generally used for activation of the BCR in-vitro [3,24–27]. There
are some cell lines (eg. SUDHL4 [16], DOHH2 [19]), however,
that are reported to utilize IgG (immunoglobulin G) instead of
IgM. The cell lines used in this study (Z138, OciLy18, REC1 and
SUDHL4) were all treated with both anti-IgM- and anti-IgG
antibodies to trigger B cell receptor. To trigger CD20 signaling we
applied anti-CD20 antibodies called rituximab and LT20,
respectively.
As Fcc receptors can interfere with the BCR signaling pathway
[28], we included LT20 containing a murine Fc-part and F(ab’)2-
fragments of anti-IgM antibodies to check, if there was an
influence of the human Fc-part of the applied whole antibodies
capable of binding to Fcc receptors.
Of the four cell lines tested REC1 responded most strongly to
anti-IgM and anti-IgG antibody treatment in terms of numbers of
deregulated genes, while OciLy18 and Z138 showed fewer gene
expression changes. SUDHL4 responded strongly to anti-IgG
antibody whereas after treatment with anti-IgM antibodies almost
no significant changes in gene expression occurred (Table 1).
FACS (fluorescence activated cell sorting) analysis confirmed that
these cells only express IgG but not IgM on the cell surface. This is
consistent with previous reports [16].
These experiments showed that both anti-IgM and anti-IgG
treatments were able to trigger specific transcription changes.
Comparison of transcriptional changes after treatment
with anti-IgM and anti-IgG antibodies
As expected treatment of Ocily18 with anti-IgM antibodies or
anti-IgM F(ab’)2-fragment showed extensive overlap with regard to
gene expression changes but also with treatment with anti-IgG
antibodies (Table 2).
Similar results were obtained with the cell line Z138. While
Z138 cells in terms of number of gene expression changes
responded equally well to cross-linking of IgG and IgM, the
OciLy18 cells were three-fold more responsive to anti-IgM versus
anti-IgG treatment. As a consequence, the overlap of the
transcriptional changes induced by the two treatments was larger
in the latter cells. In REC1 cells due to even stronger gene
expression responses the overlap was even more extensive.
The large overlap in the gene expression responses to the whole
anti-IgM and the anti-IgM F(ab’)2-fragment observed for all three
cell lines attests to the high technical and biological reproducibility
of the anti-IgM response. In general fewer genes responded to
anti-IgM compared to anti-IgM-F(ab’)2 treatment in these three
cell lines. This might reflect inhibitory effects exerted by the Fc
part via binding to FCGR2.
The higher variability of the anti-IgG response of the three cell
lines correlated with the differences in the levels of cell surface
exposed IgG molecules. Although all antigen-binding membrane
immunoglobulins, irrespective of the isotype, associate with the
CD79a/b chains, it has been previously shown that BCRs
containing IgM cytoplasmic tails are regulated by co-receptor
CD22, whereas those containing IgG cytoplamic tails are not
[29,30]. In agreement with this, in all cell lines that represent an
immature B-cell state and still express IgM type BCRs the two
Table 1. Number of up and down regulated genes.
Treatment/cells Rituximab LT20 Anti-IgM-F (ab’)2 Anti-IgM Anti-IgG
Isotype/
human IgG
OciLy18 1 6 434 383 141 0
Z138 10 15 437 283 506 1
REC1 108
245 (F (ab)2)
445 1412 1190 1028 70
SUDHL4 509 637 40 4 680 0
Filter criteria: mean .100, call .0.5, |fold change| .2.
doi:10.1371/journal.pone.0016596.t001
Table 2. Overlapping genes between different treatments.
Treatment/cells Rituximab vs. LT20 Anti-IgM vs. Anti-IgM-F (ab’)2 Anti-IgM/F (ab)2 vs. anti-IgG Anti-BCR vs. anti-CD20
OciLy18 NA 312 102 NA
Z138 NA 246 181 NA
REC1 98* 977 768 89
SUDHL4 436 NA NA 342**
*Intersection of genes deregulated by rituximab, rituximab-F(ab’)2 and LT20.
**Only anti-IgG antibody as anti-BCR treatment.
doi:10.1371/journal.pone.0016596.t002
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represent a memory B-cell state and only respond to anti-IgG but
not to anti-IgM treatment with gene expression changes.
Expression of CD22 and other potential co-receptors of the
BCR as well as markers of differentiation were determined by
flow-cytometry (and confirmed by mRNA expression) to stage the
cell lines studied (Table 3 and 4). CD22 is expressed in all cell lines
except Z138. The expression pattern of other co-receptors like
CD10, CD27, CD138 also points to a plasmablastoid phenotype
of Z138. CD27 expression indicates ongoing differentiation but is
missing in Z138, whereas SUDHL4 expresses CD27 confirming
the memory B-cell state of these cells.
In these cell lines anti-IgM antibodies triggered a BCR signaling
like cascade leading to characteristic gene regulation responses. A
very similar/overlapping transcription pattern was triggered by
anti-IgG antibodies. This allowed using anti-IgG antibodies as an
alternative trigger for BCR activation in a cell line that lacks IgM
but exposes IgG, as is the case with SUDHL4.
Transcription changes induced by anti-CD20 antibodies
Although Z138 and OciLy18 express CD20 on their cell surface
(Table 3) these cell lines did not or only very little respond to anti-
CD20 antibodies in terms of transcriptional changes. This
indicates that CD20 expression alone at the cell surface is not
sufficient to trigger substantial transcriptional responses.
In SUDHL4 and REC1 anti-CD20 treatment elicited extensive
changes in transcription: Treating SUDHL4 with rituximab and
LT20 resulted in an extensive overlap of deregulated genes with
only very few unique deregulated genes (Table 2). The remarkable
concordance between the transcription patterns of the two
different type I anti-CD20 antibodies strongly indicates that the
observed effects were target-mediated. In REC1 cells transcrip-
tional changes after treatment with rituximab or its F(ab’)2-
fragment were less pronounced than changes after LT20
treatment. Not unexpectedly, the same genes responded to
treatment with rituximab and its F(ab’)2-fragment. These genes
are a subset of the larger panel that was deregulated by LT20
treatment.
These results show that in 2 out of 4 cell lines studied specific
transcription changes were induced by anti-CD20 treatment,
independent of the isotype of antibody used.
Comparison of expression changes induced by anti-CD20
and anti-BCR treatment
Having checked the consistency of the treatments with
antibodies against either CD20 or BCR we compared anti-
CD20 with anti-BCR treatment.
With SUDHL4 the transcription patterns overlapped in 342
deregulated genes (Figure 1A and B; Table 2, Individual genes are
listed in Table S1.) i.e. 48% of the anti-CD20 pattern were
covered by the BCR pattern. The corresponding comparison for
REC1 results in an overlap of 92% (Figure 1C and D, 415 genes
overlap with anti-BCR treatment out of 452 deregulated genes
after anti-CD20 treatment. Individual genes for intersection of
union lists are listed in Table S2).
Besides comparing anti-CD20 and anti-BCR treatments in
REC1 and SUDHL4 separately we also analyzed which changes
were common to both cell lines. The overlaps of the union lists are
Table 3. Antigen expression determined by FACS analysis.
CDs/cells OciLy18 Z138 REC1 SUDHL4
CD19 ++++ + +++ +++++
CD20 + ++ +++ ++++
CD21 ++ + + +
CD22 + - ++
CD27 ++ + + +++++
CD34 + + +++ ++
CD38 +++ ++++ ++ +++++
CD138 ++ ++++ + +
IgD - ++ + -
IgM ++ ++ +++ -
CD79A ++ + + + +
CD79B ++ + +
doi:10.1371/journal.pone.0016596.t003
Table 4. Antigen expression determined by Affymetrix analysis: mean expression values of untreated cells.
Gene name OciLy18 Z138 REC1 SUDHL4 Description
CD10 268 * 79 973 membrane metallo-endopeptidase
CD19 752 273 972 333 cd19 molecule
CD20 3472 3458 3988 4324 membrane-spanning 4-domains, subfamily a, member 1
CD21 * * 814 * CD21 complement component (3d/epstein barr virus) receptor 2
CD22 758 * 311 1200 cd22 molecule
CD24 1709 559 2007 123 cd24 molecule
CD27 559 * * 1603 cd27 molecule
CD34 * * * * cd34 molecule
CD38 164 521 156 397 cd38 molecule
CD138 * 119 * * syndecan 1
IgD 188 286 * * immunoglobulin heavy constant delta
IgM 4933 4005 3822 * immunoglobulin heavy constant mu
CD79A 1046 745 2653 1114 cd79a molecule, immunoglobulin-associated alpha
CD79B 2322 425 1289 653 cd79b molecule, immunoglobulin-associated beta
*below background.
doi:10.1371/journal.pone.0016596.t004
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PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16596Figure 1. Comparison of genes deregulated by different antibody treatments. Venn diagrams for numbers of up- (A) or down- (B)
regulated genes in SUDHL4 after a 4 h incubation with 10 mg/ml anti-BCR antibody (anti-IgG) and anti-CD20 antibodies (Rituximab, LT20) and Venn
diagrams for up- (C) or down- (D) regulated genes in REC1 after treatment with anti-BCR antibodies (anti-IgG and anti-IgM, respectively) and anti-
CD20 antibodies (Rituximab, Rx-F(ab’)2, LT20).
doi:10.1371/journal.pone.0016596.g001
Figure 2. Comparison of anti-BCR and anti-CD20. Venn diagrams of ‘‘Union lists’’ of up- (A) or down- (B) regulated genes after different
treatments. Cells were incubated with 10 mg/ml antibody for 4 h. Lists of similar treatments were united to ‘‘Union lists’’ for CD20 or BCR treatment
for each cell line R=REC1, S=SUDHL4.
doi:10.1371/journal.pone.0016596.g002
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cell line intersections of 306 and 310 genes exclusively deregulated
in SUDHL4 and REC1, respectively (Figure 2, Individual genes
are listed in Table S3).
This analysis suggested that the transcription changes induced
by anti-BCR and anti-CD20 antibodies partially overlap but that
the (whole) response pattern is highly cell line specific.
Comparison of activation patterns of different cell lines
Given the extensive overlaps between the responses to anti-BCR
and anti-CD20 treatments within each of the two cell lines, and yet
the small overlaps between both cell lines, we compared the BCR
transcription patterns across all four cell lines (Figure 3). Here
again the overlaps were rather small and the proportion of genes
uniquely regulated in a given cell line was much higher. Only 25
up- and 17 down-regulated genes were common in all four cell
lines (Individual genes are listed in Table S4). The deregulated
genes contained in this overlap were analyzed further with respect
to their functional context (Table 5).
To identify the functional clusters behind the genes influenced
by anti-CD20 treatment we conducted the analogous comparison
and analysis for GO annotation, Panther, Biocarta and KEGG
pathways (Table 6) as described above for the BCR response
genes. We found that many deregulated genes are associated with
cell death, stress signaling, BCR activation, immune response, and
development of hematopoietic cells.
Despite the differing transcription patterns of the two cell lines
responding to anti-CD20 and of all four cell lines responding to
anti-BCR a few genes were affected by all treatments. Of these 5
were up- and 8 were down-regulated. They comprise transcription
factors, adaptor proteins for signaling cascades, a ubiquitin ligase
and a stress kinase – proteins that are involved in the NFkB
(Nuclear factor kappa B) signaling pathway, cellular stress and
apoptosis (Table 7 and Figure 4). A noteworthy aspect is the down-
Figure 3. Comparison of anti-BCR treatments in all cell lines studied. Venn diagrams of ‘‘Union lists’’ (=Union of lists for similar treatments)
for anti-BCR treatment of up- (A) or down- (B) regulated genes in OciLy18, Z138, SUDHL4 and REC1.
doi:10.1371/journal.pone.0016596.g003
Table 5. Functional clustering of genes deregulated by anti-BCR antibodies in cell lines OciLy18, Z138, REC1 und SUDHL4.
Pathway, Functional Cluster Genes
BCR signaling/B cell activation, Immune response DAPP1, ETS1, GEM, KLF6, PIK3R3, RFXAP, VPREB3,
Transcription ETS1, IER2, MAFF, SSBP3, ZFP36L, ZFP362
Apoptosis, cellular response to stress, cellular response to unfolded protein RNF144B, SGK1, SQSTM1, SRGN, PPP1R15A
MAPK signaling/p38 Kinase signaling DDIT3, MAPK3, SGK1, TESK1
N-Glycan biosynthesis, Other glycan degradation/Spingolipid metabolism/Lysosome MGAT4B, NEU1 (=Sialidase1)
Mitotic cell cycle, JAK/STAT signaling/Acute myeloid leukaemia SAC3DC1, OIP5, PIM1
Cytoskeleton/cell-substrate –junction APBB1IP, MICAL1
Fc gamma R mediated phagocytosis VASP
NFkB signaling NFKBID
Antigen Processing and presentation RFXAP
Cellular homeostasis GLRX
GPCR signalling RGS1
Glucose uptake SLC2A3
Base excision repair NEIL3
mRNA processing, Dicer pathway, mRNA cleavage EIF2C2
TGF beta signalling C5orf13
doi:10.1371/journal.pone.0016596.t005
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DAPP1, ETS1 and VPREB3. Another interesting finding was the
induction of BIC - a gene locus for miRNA155.
The gene expression results suggested that antibodies against
CD20 and antibodies against BCR share common signaling
pathway components.
Influence of SYK inhibition or siRNA mediated SYK down-
regulation on both anti-CD20 and anti-BCR treatment
Based on the findings outlined above, we hypothesized that the
CD20 signaling cascade also contains the kinase SYK. In the BCR
pathway, SYK acts downstream of the signaling molecules
CD79a/b and upstream of NFkB or other signaling cascades
towards the nucleus.
The cytokines CCL3/4 are easy to monitor, secreted proteins
whose transcription is potently induced in response to rituxmab
[31] and BCR activation. We therefore pre-incubated SUDHL4
cells with two known SYK inhibitors [32], applied the stimulatory
antibodies and measured the amount of secreted CCL3/4
(Figure 5A). As expected, SYK inhibitors I and IV abrogated
the CCL3/4 secretion induced by either anti-IgG antibodies or
anti-CD20 antibodies.
We also silenced Syk in SUDHL4 via siRNA-mediated
downregulation. Syk knockdown was confirmed by FACS analysis:
Mean intensity of controls was 409 (relative light units), for Syk
knockdown 262 indicating a 60% reduction of Syk surface
expression after subtraction of auto fluorescence (177). This
resulted in a statistically significant reduction of CCL3/4
induction of 37% and 38% for anti-BCR treatment and 25%
and 28% for rituximab, respectively (Figure 5B).
Since both, direct inhibition as well as silencing of the kinase
Syk abrogated antibody induced cytokine induction we concluded
that BCR cascade component Syk indeed plays a role for both
CD20 and BCR mediated signaling.
Discussion
In this study, we demonstrated that anti-CD20 and anti-BCR
antibodies induce similar transcriptional changes. BCR-stimulated
transcription patterns were elicited in four NHL cell lines by using
antibodies against the immunoglobulin part of the BCR
41,b ei t
IgM or IgG. Although there might be differences in the dynamics
of internalization by artificially crosslinking BCRs with agonistic
antibodies versus antigens that naturally crosslink the BCR [33]
this seems of minor importance for our study comparing the
transcriptional responses to various antibody treatments.
Treatment of cells with anti-IgM and anti-IgG antibodies
induces transcription patterns related to immune response and
BCR activation including components that play important roles in
the BCR signaling pathway itself. A literature derived list of 61
genes for BCR activation overlaps in 16 genes for Ocily18, in 14
genes for REC1, in 30 genes for SUDHL4 and in 22 for Z138. As
shown here the transcription changes induced by BCR stimulation
of four cell lines have very few deregulated genes in common. This
is most likely due to the different origin of the lines (Ocily18 and
SUDHL4 are DLBCL, Z138 and REC1 are Mantle cell
lymphoma cell lines) that reflects different developmental stages
Table 6. Functional clustering of genes deregulated by anti-CD20 antibodies in SUDHL4 cells und REC1 cells (KEGG-, Panther- und
Biocarta, GO terms).
Pathway/Functional Cluster Genes
Apoptosis, Cell death ADRB2, BCL2L11, BCL2A1, CDKN2C, ETS1, RNF144B, SRGN, TXNIP, TNFAIP3,
BCR, immune response CD79B, ETS1, FCGR2B, DAPP1, BLK, VPREB3
MAPK signaling, p38 signaling DUSP5, RPS6KA5, C21orf7, PTPN18, TRIB1, TXNIP
Transcription regulation, regulation of RNA stability ETS1, IRF2BP2, SSBP3, (TRIM22), ZFP36L1
Calcium signaling, response to calcium ion ATP2A3, KCNMB4
Fcgamma mediated phagocytosis FCGR2B, NCF1, VASP
Cell cycle, cell division CDKN2C, TXNIP
ECM receptor interaction, cell adhesion HMMR, ITGB7
Endocytosis RAB11FIP4
Cellular response to stress INSIG1, TXNIP, TRIB1
NFkB pathway NLRC3, NDFIP2, TNFAIP3
Arachidonic acid metabolism ALOX5, PTGER4
GPCR signaling RABGAP1L
P53 signaling DDB2, CDKN2C
Proteolysis NAPSB, SERPINA9
Cytoskeleton, intracellular trafficking APBB1IP, SNX8, DAAM1
RNA degradation EXOSC4
Pathways in Cancer ETS1
Pyrimidine metabolism UPP1
Aldosteron regulated sodium absorption SGK1
NOD-like receptor signaling TNFAIP3
T cell activation TRVD2, TRA
TGF beta signaling C21orf7
doi:10.1371/journal.pone.0016596.t006
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be used as a marker of maturity: Naı ¨ve B cells lack it, activated B
and memory cells express it moderately and plasma cells express it
strongly. We tried to stage the cell lines according to their
expression of this and other known lineage specific CDs but as
previously described in the literature [34] we found that
lymphoma cell lines express marker combinations that do not fit
the expression scheme for normal B cell development.
The fact that only two of four cell lines were responsive to anti-
CD20 antibodies diminishes the options for comparisons, but
proves that the anti-CD20 antibodies used were not inducing
unspecific effects like general cytotoxicity.
Citerra el al. reported that rituximab induces different but
overlapping sets of genes [35]. Interestingly, out of 16 genes described
by them to be up regulated by anti-CD20 antibodies in their DHL4
cell line we found 9 (RGS2, DUSP2, IER2, NR4A1, ZFP36, FOS,
ID3, ZFP36L1, CD83) to be up regulated in our data set, too.
A very interesting change in expression was observed for BIC,
the locus for the miRNA155. BIC has been reported to be highly
expressed and further inducible by BCR stimulation in DLBCL
tumors of the activated B cell like phenotype [36]. Normally,
miRNAs should not be detected by Affymetrix profiling with the
HG-U133 plus 2.0 chip, but it is known that the BIC transcript has
a poly A-tail [36,37]. This explains why it was detected with our
sample preparation using oligo-dT-primed cDNA synthesis.
Why some NHL cell lines are responsive to antibodies against
CD20 and others are not is still a matter of debate. It has been
postulated that the amount of CD20 on the cell surface influences
the response to anti-CD20 antibodies as cells with high CD20
expression respond strongly, while cells with low CD20 expression
do not. However some cell lines are able to respond to anti-CD20
antibody treatment only when the antibodies are hyper-crosslinked
[16] indicating that responses do depend on the amount of
crosslinked CD20. But that does not explain why cell lines bearing
comparable amounts of CD20 can either be responders or not.
Based on our results, we can rule out the hypothesis that cell lines
non-responsive to rituximab treatment have a defect in their BCR
signaling cascade, as the non-responding cell lines Ocily18 and
Z138 respond to BCR-crosslinking.
Kheirallahetal.recentlyprovidedevidencefor interactionofCD20
and BCR signaling in the proximal part of the cascade and proposed
mutual inhibition of their signals [19]. Our study adds some
confirmatory evidence to the latter point, since both types of
treatment downregulated important components of the BCR
signaling cascade. Assuming that both membrane proteins stimulate
the same pathway and activate negative feedback loops by regulating
the same transcriptional targets or activating inhibitory phosphatases
then the pathway would be inhibited for both signals as well.
Moreover Kheirallah et al. show that rituxmab leads to disorganiza-
tion of lipid rafts and this seems to impede BCR signaling directly.
Antibodies might interact with cell surfaces not only with their
specific target antigen via their CDRs but also via their generic
(human) Fc-part with Fcc receptors and one of these, FCGR2B (Fc
gamma receptor 2 B), is known to interact with BCR signaling in an
inhibitory manner [38–40] by recruiting phosphatase SHIP1 via its
ITIM (immunoreceptor tyrosine-based inhibitory motif) [41,42]. We
therefore used in this study also F(ab’)2 fragments besides whole
antibodies and antibodies with Fc-portions of either human or mouse
Table 7. Genes that are common deregulated in all four cell lines by anti-BCR antibodies and in SUDHL4 and REC1 by anti-CD20
antibodies.
Gene Symbol Function/Description
Up regulated genes
BIC - Genlocus for miRNA-155
- is regulated by PKC and NFKB after BCR stimulation [36]
SGK1 - a Serine/Threonine kinase, important for cellular stress response
- regulated GSK3 and binds IKK (NFkB Pathway)
SRGN - is associated with Granzyme/Perforine complex, perhaps a mediator of apoptosisi
- regulates secretion of TNFa
VASP - a adaptor protein, involved in intracellular signal transduction, that regulates interaction between integrines and intercellular matrix
- is regulated by PKA and PKG
ZFP36L1 - a Zinc finger transcription factor, activated by cellular stess
- is a early response gene
Down regulated genes
APBB1IP - plays role in signaltransduction of Ras to remodel the actin cyto skeleton
- interacts with VASP
- plays role in TCR activation
C5orf13 - open reading frame without known funtion
DAPP1 - adaptor protein, regulates JNK, RAC1 and MAPK signaling cascades
ETS1 - a transcription factor, plays role in stem cell development, cellular senescence and death
- associated with BCR stimulation [23]
- regulates CDKN1A (p21, cell cycle inhibitor), MDM2 (p53 antagonist) and MMPs
GLRX - a thioltransferase, important in NFkB signaling pathway
RNF144B - a ring finger protein; E3 ubiquitin ligase, avoiding spontaneous apoptosis [47] (BRDC2= RNF144B)
- is regulated by p53
- ubiquitinates CDKN1A
SSBP3 - a single strand binding protein, transcription regulator
VPREB3 - associated with m chain in pre-B cell receptor synthesis, supposed to be involved in its transport
doi:10.1371/journal.pone.0016596.t007
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respect to this issue, maybe due to different FCGR2B expression on
the cell surface or different sensitivity of the receptor [43].
A crucial part downstream in the BCR signaling cascade (that is
repressed by anti-CD20 and anti-BCR antibodies in SUDHL4) is
Syk. Syk inhibition blocks BCR signaling and is being investigated
for the therapy of lymphoma [44]. The applied inhibitors I and IV
are very specific, indicated by the fact that the reported
biochemical IC50s for Syk are very low (14 nM [45] and 10 nM
[46] respectively) and the IC50 of Inhibitor IV for related kinases
is greater than 5 mM [45] and the reported cellular EC50s are
313 nM [45] and 110 nM [46] respectively. Direct Syk inhibition
affected antibody mediated CCL3/CCL4 secretion which con-
firms that the signaling induced by both anti-BCR and anti-CD20
antibodies involves Syk. The same effect can be achieved by
siRNA mediated silencing of Syk. It also suggests that Syk
inhibitors might interfere with anti-CD20 antibody therapy.
In conclusion our study provides evidence of considerable
similarities of transcription changes between anti-CD20 and anti-
BCR antibodies. Combined with previous findings of interference
this points to a shared pathway and provides further insight into
the mode of action of anti-CD20 antibodies.
Figure 4. Interactions between deregulated genes. IPA generated network of interactions between genes deregulated by anti-CD20 antibodies
in SUDHL4 and REC1. The red circle marks genes which are also deregulated by all anti-BCR treatments. Interestingly this unbiased analysis displays
deregulations of BCR components and the downstream signaling pathway.
doi:10.1371/journal.pone.0016596.g004
Profiling of Antibodies against CD20 and BCR
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e16596Figure 5. Repression of chemokine CCL3/4 induction caused by Syk inhibition and silencing. (A) CCL3 secretion in SUDHL4 induced by
anti-IgG antibodies and anti-CD20 antibodies and its inhibition by Syk inhibitors I and IV (Calbiochem) at 1 mM and 0,32 mM respectively. Bars
represent mean of three replicates, including standard deviation (,IgG. = anti-IgG antibody, Inh. I = Syk inhibitor I, Inh. IV= Syk inhibitor IV, LT20
= murine anti-CD20 antibody, Rx-Fab’2 = F(ab’)2 fragment of rituximab). Inhibition of CCL3 (B) and CCL4 (C) secretion in SUDHL4 induced by anti-IgG
antibodies or rituximab after siRNA-mediated Syk silencing. Results represent at least three independent experiments. Students t-test for ‘‘Negative
controls’’ vs. ‘‘SYK-knockdown’’: for CCL3 secretion after anti-IgG treatment p=6.8*10
27, Rx treatment p=7.4*10
23. For CCL4 secretion after anti-IgG
treatment p=2.1*10
26, Rx treatment p=2.5*10
24. (anti-IgG = anti-IgG antibody, Rx = rituximab, Neg. controls = RISCfree and Luciferase-siRNA
transfections, respectively; SYK knock down = Syk-siRNA transfections).
doi:10.1371/journal.pone.0016596.g005
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Cells and reagents
DLBCL cell line OciLy18 (Ontario Cancer Institute) was grown
in IMDM supplemented with 20% FCS, 50 mM b-Mercaptoeth-
anol, 25 mM Hepes und 2 mM Glutamine.
MCL cell line Z138 (Glycart) was grown in DMEM
supplemented with 10% FCS and 2 mM Glutamine. MCL cell
line REC-1 (DSMZ) and DLBCL cell line SUDHL-4 were grown
in RPMI 1640 supplemented with 10% FCS and 2 mM
Glutamine. All cell lines were cultured at 37uC in humidified
5% CO2 atmosphere.
For each microarray analysis 7*10
6 cells in 7 ml suspension
were treated for 4 h with 10 mg/ml whole antibody (Rituximab
(Roche), LT20 (Exbio), anti-IgG antibody, anti-IgM antibody
(SouthernBiotech), isotype (SouthernBiotech). To achieve equi-
molar concentrations we applied 6,6 mg/ml of F (ab’)2 fragment of
anti-IgM antibody (SouthernBiotech). Cells were lysed with
RLTM lysis buffer (Qiagen).
siRNA transfection
Cells were transfected by electroporation using AMAXA, Kit V
(Lonza) Program O-017. Briefly 5*10
6 cells were transfected with
1 ng SYK siRNA or control siRNAs RISC free, Luciferase
(Dharmacon). Cells were seeded at 5*10
5 cells per ml and protein
depletion was assessed 40 h after transfection by FACS analysis.
Microarray analysis
The cRNA microarray analysis was performed using genechip
HG U133 Plus 2.0 (Affymetrix). Probe labeling was performed as
described previously. Briefly, total mRNA was reverse transcribed
and cDNA was transcribed in-vitro with labelled nucleotides.
Labelled and fragmented cRNA was hybridized to the chip over
night. Analyses were performed using GENECHIPH Operating
Software (GCOS, Affymetrix). Experiments were done with three
replicates.
All data are MIAME compliant and were deposited in GEO
with the accession number GSE23394. http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?token=lnyxheqicsesilc&acc=GSE23394.
Data analysis comprised three steps: 1) filtering 2) consistency
check via intersecting 3) characterization.
The data were filtered by applying the following criteria: at least
in one of two compared samples mean .100, call .0.5, |fold
change| .2.
Lists with filtered genes were compared with each another using
in-house Excel ad-ins for generating unions and intersections and
pictures were generated with VENNY (Oliveros J.C. (2007)
VENNY. An interactive tool for comparing lists with Venn
Diagrams. http://bioinfogp.cnb.csic.es/tools/venny/index.html).
GO annotations were retrieved from http://david.abcc.ncifcrf.
gov/tools.jsp. Further analysis was conducted using IPA –
Ingenuity pathway analysis (Ingenuity Systems).
SYK-inhibition and CCL3/4-ELISA
To quantify the amount of CCL3 released upon antibody
induced BCR- or CD20-crosslinking we applied the QuantikineH
Kits (Human CCL3/MIP1-alpha and Human CCL4/MIP1-beta,
R&D Systems). ELISA was performed according to the manufac-
turer’s directions. Briefly 3*10
5 cells per well were seeded into
96well plates and pre-incubated with Syk-inhibitors I or IV
(BAY61-3606) (Calbiochem) at various concentrations for 1 h.
Antibodies were added and analyses were performed after
additional 4 h.
Flow cytometry/FACS
Cells were washed with cold PBS (GIBCO), and either blocked
with human serum (GIBCO) or for intracellular target detection
fixed with para-formaldehyde, permeabilized with saponine and
then stained on ice for 20 min with FITC-, APC- or PE-labelled
mAbs (Jackson Immunoresearch, BD Biosciences) and analysed by
flow cytometry (FACS CANTO II, BD Biosciences). Analysis was
performed with DIVA software (BD Biosciences).
Supporting Information
Table S1 Genes deregulated in SUDHL7 cells by anti-
BCR and anti-CD20 treatment. Green fill means down
regulation . 2 fold, red fill up regulation . 2 fold; Symbol =
official gene symbol.
(XLS)
Table S2 Genes deregulated in REC1 cells: overlap
between union lists for anti-BCR and anti-CD20 treat-
ment. Green fill means down regulation . 2 fold, red fill up
regulation . 2 fold; Symbol = official gene symbol.
(XLS)
Table S3 Overlapping genes in SUDHL7 and REC1 cells
deregulated by anti-CD20 and anti-BCR treatment.
Green fill means down regulation . 2 fold, red fill means up
regulation . 2 fold; Symbol = official gene symbol.
(XLS)
Table S4 Genes deregulated by BCR stimulation in
SUDHL7, REC1, Z138 and OciLy18 cells. Green fill means
down regulation . 2 fold, red fill means up regulation .2 fold;
Symbol = official gene symbol.
(XLS)
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